Compare BOLT & MEGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOLT | MEGL |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.0M |
| IPO Year | 2021 | 2021 |
| Metric | BOLT | MEGL |
|---|---|---|
| Price | $3.67 | $1.09 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $29.00 | N/A |
| AVG Volume (30 Days) | ★ 31.2K | 6.9K |
| Earning Date | 11-11-2026 | 10-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,695,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,525.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $3.10 | $0.87 |
| 52 Week High | $7.20 | $1.90 |
| Indicator | BOLT | MEGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | N/A |
| Support Level | $3.13 | N/A |
| Resistance Level | $4.34 | N/A |
| Average True Range (ATR) | 0.32 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 40.48 | 0.00 |
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The company's offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.